- Home
- GNPX vs MULN Comparison
GNPX vs MULN Comparison
Compare GNPX & MULN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- MULN
- Stock Information
- Founded
- GNPX 2009
- MULN 2014
- Country
- GNPX United States
- MULN United States
- Employees
- GNPX N/A
- MULN N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- MULN Auto Manufacturing
- Sector
- GNPX Health Care
- MULN Consumer Discretionary
- Exchange
- GNPX Nasdaq
- MULN Nasdaq
- Market Cap
- GNPX 6.6M
- MULN 6.5M
- IPO Year
- GNPX 2018
- MULN N/A
- Fundamental
- Price
- GNPX $0.23
- MULN $0.62
- Analyst Decision
- GNPX
- MULN
- Analyst Count
- GNPX 0
- MULN 0
- Target Price
- GNPX N/A
- MULN N/A
- AVG Volume (30 Days)
- GNPX 3.6M
- MULN 8.0M
- Earning Date
- GNPX 08-08-2025
- MULN 08-11-2025
- Dividend Yield
- GNPX N/A
- MULN N/A
- EPS Growth
- GNPX N/A
- MULN N/A
- EPS
- GNPX N/A
- MULN N/A
- Revenue
- GNPX N/A
- MULN $8,931,612.00
- Revenue This Year
- GNPX N/A
- MULN N/A
- Revenue Next Year
- GNPX N/A
- MULN N/A
- P/E Ratio
- GNPX N/A
- MULN N/A
- Revenue Growth
- GNPX N/A
- MULN 2136.62
- 52 Week Low
- GNPX $0.20
- MULN $0.59
- 52 Week High
- GNPX $3.97
- MULN $154,200,000.00
- Technical
- Relative Strength Index (RSI)
- GNPX 40.22
- MULN 20.72
- Support Level
- GNPX $0.22
- MULN $1.62
- Resistance Level
- GNPX $0.32
- MULN $1.64
- Average True Range (ATR)
- GNPX 0.03
- MULN 0.91
- MACD
- GNPX -0.01
- MULN 152.97
- Stochastic Oscillator
- GNPX 22.07
- MULN 0.66
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.